1. Scrip
  2. >>Business
  3. >>Earnings

AstraZeneca To Remain In Vaccines For The Long Haul

Posts Strong Q3 Numbers

 
• By Kevin Grogan

The highs and lows experienced with its COVID-19 vaccine Vaxzevria have not deterred the UK giant from keeping a presence in the field and CEO Pascal Soriot told Scrip that the path could mirror the decade-long journey AstraZeneca had in oncology before it achieved sustained success.  

Pascal Soriot
Pascal Soriot • Source: AstraZeneca

AstraZeneca PLC CEO Pascal Soriot has ended rumors that the company could exit the vaccines space now that sales of its COVID-19 jab Vaxzevria are declining by telling Scrip that the UK major will be in the space for years to come.

Soriot had suggested over the summer that AstraZeneca may not stay in the vaccine game for the long term. The company played a leading role when the COVID-19 pandemic struck, delivering a not-for-profit vaccine at speed but Vaxzevria never got approval in the US and despite positive data, governments in the EU and elsewhere decided to plump for the mRNA-based vaccines such as Pfizer Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.

Takeda Plans US Investment But Sees Little Impact From Tariffs

 
• By Alaric DeArment

The Japanese drug maker is on track for three pivotal Phase III readouts and two regulatory submissions in 2025.

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.